Heat Biologics, Inc. (NASDAQ:HTBX) – Investment analysts at Zacks Investment Research issued their FY2021 earnings per share estimates for Heat Biologics in a report released on Tuesday, April 6th. Zacks Investment Research analyst J. Vandermosten expects that the biopharmaceutical company will post earnings of ($0.99) per share for the year. Zacks Investment Research also issued estimates for Heat Biologics’ FY2022 earnings at ($1.19) EPS.

HTBX has been the subject of several other research reports. Cantor Fitzgerald started coverage on shares of Heat Biologics in a research report on Tuesday, March 2nd. They issued an “overweight” rating and a $22.00 price target for the company. Alliance Global Partners boosted their price target on Heat Biologics from $5.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, February 9th. B. Riley reissued a “buy” rating on shares of Heat Biologics in a report on Thursday, December 24th. Finally, Maxim Group reiterated a “buy” rating and set a $14.00 target price on shares of Heat Biologics in a research report on Tuesday, February 9th.

Shares of NASDAQ HTBX opened at $7.36 on Thursday. Heat Biologics has a one year low of $3.22 and a one year high of $30.10. The business has a fifty day simple moving average of $8.26 and a 200 day simple moving average of $4.86.

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in shares of Heat Biologics during the third quarter valued at approximately $34,000. Los Angeles Capital Management LLC bought a new stake in shares of Heat Biologics during the fourth quarter worth $98,000. State Street Corp acquired a new position in shares of Heat Biologics during the third quarter valued at $141,000. Wells Fargo & Company MN increased its position in Heat Biologics by 3,083.4% in the fourth quarter. Wells Fargo & Company MN now owns 29,001 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 28,090 shares during the period. Finally, Morgan Stanley raised its holdings in Heat Biologics by 138.6% during the 3rd quarter. Morgan Stanley now owns 169,945 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 98,715 shares during the last quarter. 49.84% of the stock is owned by institutional investors.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.